Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?

SIMPLE SUMMARY: Immunotherapy is changing the therapeutic landscape of many hematologic diseases. Nevertheless, in acute myeloid leukemia (AML) the anti CD33 antibody-drug conjugate gemtuzumab ozogamicin is the only approved drug. In this review, we aimed at reporting biological mechanisms and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbullushi, Kordelia, Rampi, Nicolò, Serpenti, Fabio, Sciumè, Mariarita, Fabris, Sonia, De Roberto, Pasquale, Fracchiolla, Nicola Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221207/
https://www.ncbi.nlm.nih.gov/pubmed/35740657
http://dx.doi.org/10.3390/cancers14122994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221207/
https://www.ncbi.nlm.nih.gov/pubmed/35740657
http://dx.doi.org/10.3390/cancers14122994

Ejemplares similares